GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entera Bio Ltd (FRA:5DT) » Definitions » Forward PE Ratio

Entera Bio (FRA:5DT) Forward PE Ratio : 0.00 (As of May. 29, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Entera Bio Forward PE Ratio?

Entera Bio's Forward PE Ratio for today is 0.00.

Entera Bio's PE Ratio without NRI for today is 0.00.

Entera Bio's PE Ratio for today is 0.00.


Entera Bio Forward PE Ratio Historical Data

The historical data trend for Entera Bio's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entera Bio Forward PE Ratio Chart

Entera Bio Annual Data
Trend
Forward PE Ratio

Entera Bio Quarterly Data
Forward PE Ratio

Competitive Comparison of Entera Bio's Forward PE Ratio

For the Biotechnology subindustry, Entera Bio's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Entera Bio's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entera Bio's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Entera Bio's Forward PE Ratio falls into.



Entera Bio Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Entera Bio  (FRA:5DT) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Entera Bio Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Entera Bio's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Entera Bio (FRA:5DT) Business Description

Traded in Other Exchanges
Address
Minrav Building - Fifth Floor, Kiryat Hadassah, Jerusalem, ISR, 9112002
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Entera Bio (FRA:5DT) Headlines

No Headlines